Authors
Sibaprasad Bhattacharyya, Ling Wei & Jianfeng Shi
Summary
A robust protocol has been developed for producing clinical-grade 89Zr-panitumumab as an immuno-PET probe to evaluate EGFR- targeted therapy. In this protocol, clinical-grade panitumumab is bio-conjugated with desferrioxamine chelate and subsequently radiolabeled with 89Zr resulting in high radiochemical yield (> 70 %, n = 3) and purity (> 98%, n = 3). All quality control (QC) tests were performed according to USPspecifications (USP general chapter <823>). QC tests showed that the 89Zr-panitumumab met all specifications for human injection. This protocol describes a step-by-step method for the facile synthesis and quality control tests of 89Zr-panitumumab for medical use. The entire process of bioconjugation, radiolabeling, and all QC tests take about 5 h.Further details
The protocol was published on Protocol Exchange on 26 September 2013. To see the entire protocol, click on the source link.Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 455
- Comments 0